Cargando…
Validation of a novel point of care testing device for sickle cell disease
BACKGROUND: Sickle cell disease is one of the most common inherited blood disorders. Universal screening and early intervention have significantly helped to reduce childhood mortality in high-resource countries. However, persons living in low-resource settings are often not diagnosed until late chil...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573998/ https://www.ncbi.nlm.nih.gov/pubmed/26377572 http://dx.doi.org/10.1186/s12916-015-0473-6 |
_version_ | 1782390546582470656 |
---|---|
author | Kanter, Julie Telen, Marilyn J. Hoppe, Carolyn Roberts, Christopher L. Kim, Jason S. Yang, Xiaoxi |
author_facet | Kanter, Julie Telen, Marilyn J. Hoppe, Carolyn Roberts, Christopher L. Kim, Jason S. Yang, Xiaoxi |
author_sort | Kanter, Julie |
collection | PubMed |
description | BACKGROUND: Sickle cell disease is one of the most common inherited blood disorders. Universal screening and early intervention have significantly helped to reduce childhood mortality in high-resource countries. However, persons living in low-resource settings are often not diagnosed until late childhood when they present with clinical symptoms. In addition, confirmation of disease in affected individuals in the urgent care setting is limited in both high- and low-resource areas, often leading to delay in treatment. All of the current diagnostic methods rely on advanced laboratory systems and are often prohibitively expensive and time-consuming in low-resource settings. To address this need, the Sickle SCAN™ test has been developed to diagnose sickle cell disease and sickle cell trait at the point of care without electricity or advanced equipment. METHODS: This study was conducted to evaluate and validate the diagnostic accuracy of the Sickle SCAN™ test, a novel point of care test for sickle cell disease. Thus, we describe the laboratory testing and clinical validation of the Sickle SCAN™ test in individuals >1 year of age using capillary blood. The Sickle SCAN™ test was created using advanced, qualitative lateral flow technology using capillary blood to identify the presence of hemoglobin A, S, and C allowing for detection of results with the naked eye. RESULTS: Laboratory testing using venous blood demonstrated 99 % sensitivity and 99 % specificity for the diagnosis of HbSS, HbAS, HbSC, HbAC, and HbAA. Seventy-one subjects underwent capillary blood sampling at the point of care for further validation. This test detected the correct A, S, and C presence with an overall diagnostic accuracy of 99 % at the bedside. CONCLUSION: The Sickle SCAN™ test has the potential to significantly impact the diagnosis and treatment for sickle cell disease worldwide as well as enhance genetic counseling at the point of care. Further validation testing will be conducted in newborns in resource-poor settings in upcoming studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-015-0473-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4573998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45739982015-09-19 Validation of a novel point of care testing device for sickle cell disease Kanter, Julie Telen, Marilyn J. Hoppe, Carolyn Roberts, Christopher L. Kim, Jason S. Yang, Xiaoxi BMC Med Technical Advance BACKGROUND: Sickle cell disease is one of the most common inherited blood disorders. Universal screening and early intervention have significantly helped to reduce childhood mortality in high-resource countries. However, persons living in low-resource settings are often not diagnosed until late childhood when they present with clinical symptoms. In addition, confirmation of disease in affected individuals in the urgent care setting is limited in both high- and low-resource areas, often leading to delay in treatment. All of the current diagnostic methods rely on advanced laboratory systems and are often prohibitively expensive and time-consuming in low-resource settings. To address this need, the Sickle SCAN™ test has been developed to diagnose sickle cell disease and sickle cell trait at the point of care without electricity or advanced equipment. METHODS: This study was conducted to evaluate and validate the diagnostic accuracy of the Sickle SCAN™ test, a novel point of care test for sickle cell disease. Thus, we describe the laboratory testing and clinical validation of the Sickle SCAN™ test in individuals >1 year of age using capillary blood. The Sickle SCAN™ test was created using advanced, qualitative lateral flow technology using capillary blood to identify the presence of hemoglobin A, S, and C allowing for detection of results with the naked eye. RESULTS: Laboratory testing using venous blood demonstrated 99 % sensitivity and 99 % specificity for the diagnosis of HbSS, HbAS, HbSC, HbAC, and HbAA. Seventy-one subjects underwent capillary blood sampling at the point of care for further validation. This test detected the correct A, S, and C presence with an overall diagnostic accuracy of 99 % at the bedside. CONCLUSION: The Sickle SCAN™ test has the potential to significantly impact the diagnosis and treatment for sickle cell disease worldwide as well as enhance genetic counseling at the point of care. Further validation testing will be conducted in newborns in resource-poor settings in upcoming studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-015-0473-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-09-16 /pmc/articles/PMC4573998/ /pubmed/26377572 http://dx.doi.org/10.1186/s12916-015-0473-6 Text en © Kanter et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Technical Advance Kanter, Julie Telen, Marilyn J. Hoppe, Carolyn Roberts, Christopher L. Kim, Jason S. Yang, Xiaoxi Validation of a novel point of care testing device for sickle cell disease |
title | Validation of a novel point of care testing device for sickle cell disease |
title_full | Validation of a novel point of care testing device for sickle cell disease |
title_fullStr | Validation of a novel point of care testing device for sickle cell disease |
title_full_unstemmed | Validation of a novel point of care testing device for sickle cell disease |
title_short | Validation of a novel point of care testing device for sickle cell disease |
title_sort | validation of a novel point of care testing device for sickle cell disease |
topic | Technical Advance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573998/ https://www.ncbi.nlm.nih.gov/pubmed/26377572 http://dx.doi.org/10.1186/s12916-015-0473-6 |
work_keys_str_mv | AT kanterjulie validationofanovelpointofcaretestingdeviceforsicklecelldisease AT telenmarilynj validationofanovelpointofcaretestingdeviceforsicklecelldisease AT hoppecarolyn validationofanovelpointofcaretestingdeviceforsicklecelldisease AT robertschristopherl validationofanovelpointofcaretestingdeviceforsicklecelldisease AT kimjasons validationofanovelpointofcaretestingdeviceforsicklecelldisease AT yangxiaoxi validationofanovelpointofcaretestingdeviceforsicklecelldisease |